Vivozon is a global innovative drug development company established in 2008. We built an efficacy-based new drug discovery system that is clearly distinct from the existing new drug development paradigm, and discovered the non- narcotic analgesic opiranserin (VVZ-149) in less than a year. Opiranserin, which is currently undergoing global phase 3 clinical trials as a single-dose injectable for treating postoperative pain, will be expanded to various indications such as neuropathic pain and cancer pain by multiple administration routes. Vivozon boldly invests in R&D and education, expanding its pipeline to address central nervous system diseases such as addiction, schizophrenia, depression, and Parkinson’s disease.